BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Huge rotating structure of galaxies and dark matter is detected - 2A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- 3Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- 4This Tiny Neon Frog Dwells in the Clouds
- 5Instructions to Pick the Right Dental Expert for Teeth Substitution
- Climbing Mount Everest: An Individual Victory
- Choosing the Ideal Bed for Quality Rest and Solace
- The Response Uncovered: Disentangling the Secrets of the Universe
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Kendall Jenner addresses long-standing rumor about her sexuality
- Which Diet Prompts the Incomparable Wellbeing Results?
- Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- 7 Popular Vacation destinations In China
